AGIOS PHARMACEUTICALS, INC. — Director's Dealing 2021

Feb 17, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: AGIOS PHARMACEUTICALS, INC. (AGIO)
CIK: 0001439222
Period of Report: 2021-02-14

Reporting Person: FOUSE JACQUALYN A (Director, Chief Executive Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-02-14	Common stock	M	11333	—	Acquired	61761	Direct
2021-02-14	Common stock	F	3398	—	Disposed	58363	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-14	Restricted stock units	$	M	11333	Disposed		Common stock (11333.0)	Direct

Footnotes

F1: Each restricted stock unit represents a contingent right to receive one share of the issuer's common stock.

F2: The restricted stock units were granted on February 14, 2020. Beginning on February 14, 2021, the shares underlying the restricted stock units will vest in three equal annual installments.